WO2010043849A1 - Process for the preparation of rufinamide - Google Patents

Process for the preparation of rufinamide Download PDF

Info

Publication number
WO2010043849A1
WO2010043849A1 PCT/GB2009/002419 GB2009002419W WO2010043849A1 WO 2010043849 A1 WO2010043849 A1 WO 2010043849A1 GB 2009002419 W GB2009002419 W GB 2009002419W WO 2010043849 A1 WO2010043849 A1 WO 2010043849A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
azide
rufinamide
methyl
iii
Prior art date
Application number
PCT/GB2009/002419
Other languages
French (fr)
Other versions
WO2010043849A8 (en
Inventor
Rajendra Narayanrao Kankan
Dharmaraj Ramachandra Rao
Dilip Ramdas Birari
Original Assignee
Cipla Limited
Curtis, Philip, Anthony
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited, Curtis, Philip, Anthony filed Critical Cipla Limited
Priority to AU2009305255A priority Critical patent/AU2009305255B2/en
Priority to JP2011530559A priority patent/JP2012505191A/en
Priority to NZ591725A priority patent/NZ591725A/en
Priority to US13/063,440 priority patent/US8183269B2/en
Priority to CA2736703A priority patent/CA2736703A1/en
Priority to EP09744712A priority patent/EP2334653A1/en
Publication of WO2010043849A1 publication Critical patent/WO2010043849A1/en
Publication of WO2010043849A8 publication Critical patent/WO2010043849A8/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Definitions

  • the present invention relates to an improved process for the preparation of rufinamide.
  • Rufinamide is an anticonvulsant medication. It has been used in combination with other medication and therapy to treat Lennox-Gastaut spasms and various other seizure disorders.
  • Rufinamide a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.
  • the chemical name for rufinamide is 1- (2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide (formula I), and it is represented by the following structure.
  • 2,6-difluorobenzylchloride of formula Ii and sodium azide are reacted in the presence of DMSO to obtain 2-(azidomethyI)-1 ,3-difluorobenzene of formula III, which is then treated with 2-propioIic acid to give a carboxylic acid intermediate which on further reaction with methanol in the presence of sulfuric acid yields methyl 1-(2,6- difluorobenzyl)-1 H-1 ,2,3-triazo!e-4-carboxylate intermediate of formula IV. This intermediate is then isolated and further reacted with methanolic ammonia to yield rufinamide of formula I.
  • US 4,789,680 also discloses the preparation of rufinamide by reacting 2,6- difluorobenzyl azide of formula III with propiolic acid to give the corresponding carboxylic acid intermediate which is then treated with thionyl chloride and subsequently with ammonia to obtain rufinamide.
  • W 01998/002423 discloses a process for preparation of rufinamide which involves reacting 2,6-difluorobenzylazide with 2-chloroacrylonitrile.
  • the synthesis of rufinamide described in the earlier processes involves the isolation of intermediates at each step, and then subjection of the isolated intermediates to new reagents which require different conditions, solvents, temperature, etc. Due to the multistep extractive workup procedures, there is an increase in the processing time period along with an increase in the usage of solvent. Such discontinuous processes lead to lower yield, as product is lost during each isolation step and increases the effluent load. Further, the synthesis described in the prior art involves the use of environmentally unfriendly organic solvents. It is therefore evident that there is a need for an alternative process for synthesizing rufinamide which avoids multiple isolation steps, the use of multiple reaction vessels and the use of organic solvent, and which results in a high yield.
  • the object of the present invention is to provide an improved process for the preparation of rufinamide.
  • Another object of the invention is to provide a process for the preparation of rufinamide which is simple, economical and eco-friendly with reduced reaction times.
  • X is chloride and the compound of formula Il has the formula HA.
  • X is bromide and the compound of formula Il has the formula HB.
  • the azide is an alkali metal azide, an alkyl silyl azide or a phosphoryl azide.
  • the alkali metal azide may be sodium azide or potassium azide.
  • the alkali metal azide is sodium azide.
  • the alkyl silyl azide may have the formula R 3 Si-N3, wherein each R is a Ci to C 6 alkyl group, for example methyl, ethyl, n-propyl, i-propyl, butyl, pentyl or hexyl.
  • the alkyl silyl azide is trimethylsilyl azide.
  • the azide is a phosphoryl azide, for example having the formula P(O)(OR') 2 N 3 , wherein each R' is a Ci to C ⁇ alkyl group or optionally substituted aryl.
  • R' is unsubstituted phenyl.
  • the ammonia used in step (iii) may be in the form of gaseous ammonia, liquid ammonia or aqueous ammonia, preferably aqueous ammonia.
  • the concentration of the aqueous ammonia ranges from about 20% to about 25%.
  • the aqueous ammonia is added dropwise.
  • step (i) is carried out at a temperature ranging from about 60 0 C to about 80 0 C, preferably ranging from about 70 0 C to about 75 0 C.
  • the reaction time for step (i) ranges from about 25 hours to about 40 hours, and preferably from about 25 hours to about 30 hours.
  • step (ii) the methyl propiolate is added to the 2- (azidomethyl)-1 ,3-difluorobenzene intermediate of formula III dropwise at a temperature ranging from about 20 0 C to about 30 0 C (suitably about 25 0 C). Then the temperature may be raised to a temperature ranging from about 50 0 C to about 75 0 C, preferably to a temperature ranging from about 60 0 C to about 65 0 C, and the time required for the step (ii) ranges from about 4 to about 5 hours.
  • all the reaction steps are carried out in the presence of water as a solvent.
  • water is the only solvent.
  • steps (i) to (iii) are carried out without isolation of 2-(azidomethyl)-1,3- difluorobenzene of formula III and without isolation of methyl 1-(2,6-difluorobenzyl)-1 H- 1 ,2,3-triazoie-4-carboxylic acid of formula IV.
  • steps (i) to (iii) are carried out without isolation of 2-(azidomethyl)-1,3- difluorobenzene of formula III and without isolation of methyl 1-(2,6-difluorobenzyl)-1 H- 1 ,2,3-triazoie-4-carboxylic acid of formula IV.
  • neither one of these intermediates is isolated from the reaction mixture as a solid.
  • the process is a one-pot process. In other words, all the steps that result in rufinamide in the process of the present invention are carried out in a single reaction vessel.
  • telomere prepared according to the process of the present invention.
  • a pharmaceutical composition comprising rufinamide prepared according to the process of the present invention together with one or more pharmaceutically acceptable excipients.
  • rufinamide prepared according to the process of the present invention for use in treating epilepsy or subindications thereof.
  • a method of treating epilepsy or a subindication thereof comprising administering to a subject in need thereof a therapeutically effective amount of rufinamide prepared according to the process of the present invention.
  • the present invention is advantageous as it provides an improved process for preparing rufinamide which process involves the use of methyl propiolate.
  • the use of methyl propiolate in a process for preparing rufinamide is carried out in water as a solvent.
  • the process is a one-pot process.
  • the process may involve reacting 2-(azidomethyl)-1,3-difluorobenzene of formula III with methyl propiolate, to obtain methyl 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4- carboxylic acid of formula IV, and converting the methyl 1-(2,6-difluorobenzyl)-1 H-1 ,2,3- triazole-4-carboxylic acid of formula IV to rufinamide.
  • the conversion of methyl 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxylic acid of formula IV to rufinamide may comprise reacting the methyl 1-(2,6-difluorobenzyl)-1H- 1 ,2,3-triazole-4-carboxylic acid of formula IV with ammonia to obtain rufinamide.
  • the 2-(azidomethyl)-1,3-difluorobenzene of formula III may have been prepared by reacting a 2,6-difluorobenzylhalide of formula II, wherein X is chloride, bromide or iodide, with an azide to obtain the 2-(azidomethyl)-1 ,3-difluorobenzene of formula 111.
  • the process of the present invention involves the synthesis of rufinamide and may employ water as a solvent which contributes to green chemistry.
  • the present invention describes a practical, economical and efficient synthesis for the preparation of rufinamide. This process is particularly advantageous in comparison with known methods because the reaction may be carried out without isolating the intermediates formed by the preceding step.
  • the process of the present invention eliminates the risk of handling hazardous chemicals, the enhanced cost associated with multiple reactors, and it reduces the reaction time and cleanup, thus making the process more industrially viable.
  • the present invention provides a process for the preparation of rufinamide of formula I, which process comprises: (a) reacting 2,6- difluorobenzylchloride of formula HA
  • the process is carried out without isolation of 2-(azidomethyl)-1 ,3- difluorobenzene and without isolation of methyl 1-(2,6-difluorobenzyl)-1H-1 ,2,3-triazole- 4-carboxylic acid.
  • the process is carried out as a one-pot process. Alternatively, the process may be carried out with isolation of the intermediates.
  • water is the solvent in each of steps (i), (ii) and (iii).
  • Water is advantageous over the environmentally-unfriendly organic solvents as used in the prior art. Further, the use of water reduces the production cost, simplifies the work-up and minimizes the effluent disposal problem.
  • step (a) is carried out at a temperature ranging from about 60 0 C to about 80 0 C, preferably ranging from about 70 0 C to about 75 0 C.
  • reaction time to produce the azide intermediate of formula III ranges from about 25 hours to about 40 hours, and preferably from about 25 hours to about 30 hours.
  • step (b) the 2-(azidomethyl)-1 ) 3-difluorobenzene intermediate is subjected to a ring closure reaction by adding methyl propiolate dropwise at room temperature (about 25 0 C) and then allowing the temperature to rise to a temperature ranging from about 50 0 C to about 75 0 C, preferably to a temperature ranging from about 60 0 C to about 65 0 C, and the time required for the reaction ranges from about 4 to about 5 hours.
  • the amidation reaction of step (c) is carried out using ammonia which may be in the form of gaseous ammonia, liquid ammonia or aqueous ammonia, preferably aqueous ammonia.
  • ammonia which may be in the form of gaseous ammonia, liquid ammonia or aqueous ammonia, preferably aqueous ammonia.
  • the concentration of the aqueous ammonia ranges from about 20% to about 25%.
  • the aqueous ammonia is added dropwise.
  • the reaction is preferably carried out at a temperature ranging from about 65 0 C to about 80 0 C, more preferably from about 70 0 C to about 75 0 C.
  • reaction contents are cooled to room temperature (about 25 0 C), washed with water and then dried under vacuum to obtain solid rufinamide.
  • rufinamide is prepared by isolating the intermediates obtained at each preceding step.
  • the invention also relates to the use of rufinamide preferably in the form of pharmaceutical preparations for the treatment of epilepsy and subindications thereof.
  • Step B Preparation of methyl 1-(2,6-difluorobenzyl)-1H-1,2,3-tr ⁇ azole-4- carboxylic acid:
  • Step C Preparation of rufinamide: A mixture of intermediate obtained from step B (0.0098 mol, 2.5 g), and 20% aqueous ammonia solution (0.196 mol, 15 ml) was added to a 250 ml round bottom flask. The mixture was then stirred at 70 0 C to 75 0 C for 5 to 6 hours. After the completion of reaction, as monitored by TLC, the reaction mixture was cooled to room temperature. The solid obtained was filtered, washed with water and dried under vacuum at 60 0 C to 65 0 C to give a solid product (1.7 g).

Abstract

The present invention relates to a process for the preparation of rufinamide of formula (I), which process comprises: (i) reacting a 2,6-difluorobenzylhaIide of formula (II), wherein X is chloride, bromide or iodide, with an azide to obtain 2-(azidomethyl)-1,3- difluorobenzene of formula (III); (ii) reacting 2-(azidomethyl)-1,3-difluorobenzene of formula (III) with methyl propiolate to obtain methyl 1-(2,6-difluorobenzyl)-1 H-1,2,3- triazole-4-carboxylic acid of formula (IV); and (iii) reacting methyl 1-(2,6-difluorobenzyl)- 1 H-1,2,3-triazole-4-carboxylic acid of formula (IV) with ammonia to obtain rufinamide of formula (I).

Description

PROCESS FOR THE PREPARATION OF RUFINAMIDE
Technical Field
The present invention relates to an improved process for the preparation of rufinamide.
Background and Prior Art
Rufinamide is an anticonvulsant medication. It has been used in combination with other medication and therapy to treat Lennox-Gastaut spasms and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai. The chemical name for rufinamide is 1- (2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide (formula I), and it is represented by the following structure.
Figure imgf000002_0001
Rufinamide was first described in US 4,789,680. The synthetic method employed is depicted in the following reaction Scheme 1.
Figure imgf000003_0001
Methanolic ammonia
Figure imgf000003_0003
Figure imgf000003_0002
IV
Scheme 1
2,6-difluorobenzylchloride of formula Ii and sodium azide are reacted in the presence of DMSO to obtain 2-(azidomethyI)-1 ,3-difluorobenzene of formula III, which is then treated with 2-propioIic acid to give a carboxylic acid intermediate which on further reaction with methanol in the presence of sulfuric acid yields methyl 1-(2,6- difluorobenzyl)-1 H-1 ,2,3-triazo!e-4-carboxylate intermediate of formula IV. This intermediate is then isolated and further reacted with methanolic ammonia to yield rufinamide of formula I.
US 4,789,680 also discloses the preparation of rufinamide by reacting 2,6- difluorobenzyl azide of formula III with propiolic acid to give the corresponding carboxylic acid intermediate which is then treated with thionyl chloride and subsequently with ammonia to obtain rufinamide.
W 01998/002423 discloses a process for preparation of rufinamide which involves reacting 2,6-difluorobenzylazide with 2-chloroacrylonitrile. The synthesis of rufinamide described in the earlier processes involves the isolation of intermediates at each step, and then subjection of the isolated intermediates to new reagents which require different conditions, solvents, temperature, etc. Due to the multistep extractive workup procedures, there is an increase in the processing time period along with an increase in the usage of solvent. Such discontinuous processes lead to lower yield, as product is lost during each isolation step and increases the effluent load. Further, the synthesis described in the prior art involves the use of environmentally unfriendly organic solvents. It is therefore evident that there is a need for an alternative process for synthesizing rufinamide which avoids multiple isolation steps, the use of multiple reaction vessels and the use of organic solvent, and which results in a high yield.
Objects of the Invention
The object of the present invention is to provide an improved process for the preparation of rufinamide.
Another object of the invention is to provide a process for the preparation of rufinamide which is simple, economical and eco-friendly with reduced reaction times.
Summary of the Invention
According to a first aspect of the present invention, there is provided a process for the preparation of rufinamide of formula I
Figure imgf000004_0001
which process comprises: (i) reacting a 2,6-difluorobenzylhalide of formula II, wherein X is chloride, bromide or iodide, with an azide to obtain 2-(azidomethyl)-1 ,3- difluorobenzene of formula III;
Figure imgf000005_0001
(ii) reacting 2-(azidomethyl)-1 ,3-difluorobenzene of formula III with methyl propiolate to obtain methyl 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxylic acid of formula IV; and
Figure imgf000005_0002
IV
(iii) reacting methyl 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxylic acid of formula IV with ammonia to obtain rufinamide of formula I.
In an embodiment, X is chloride and the compound of formula Il has the formula HA.
Figure imgf000006_0001
HA
In an embodiment, X is bromide and the compound of formula Il has the formula HB.
Figure imgf000006_0002
HB
In an embodiment, the azide is an alkali metal azide, an alkyl silyl azide or a phosphoryl azide. The alkali metal azide may be sodium azide or potassium azide. Preferably, the alkali metal azide is sodium azide. The alkyl silyl azide may have the formula R3Si-N3, wherein each R is a Ci to C6 alkyl group, for example methyl, ethyl, n-propyl, i-propyl, butyl, pentyl or hexyl. Preferably, the alkyl silyl azide is trimethylsilyl azide. Alternatively, the azide is a phosphoryl azide, for example having the formula P(O)(OR')2N3, wherein each R' is a Ci to Cβ alkyl group or optionally substituted aryl. Suitably, R' is unsubstituted phenyl.
The ammonia used in step (iii) may be in the form of gaseous ammonia, liquid ammonia or aqueous ammonia, preferably aqueous ammonia. Suitably, the concentration of the aqueous ammonia ranges from about 20% to about 25%. Typically, the aqueous ammonia is added dropwise.
In an embodiment, step (i) is carried out at a temperature ranging from about 600C to about 800C, preferably ranging from about 700C to about 750C. In an embodiment, the reaction time for step (i) ranges from about 25 hours to about 40 hours, and preferably from about 25 hours to about 30 hours.
In another embodiment, in step (ii), the methyl propiolate is added to the 2- (azidomethyl)-1 ,3-difluorobenzene intermediate of formula III dropwise at a temperature ranging from about 200C to about 300C (suitably about 250C). Then the temperature may be raised to a temperature ranging from about 500C to about 750C, preferably to a temperature ranging from about 600C to about 650C, and the time required for the step (ii) ranges from about 4 to about 5 hours.
In an embodiment, all the reaction steps are carried out in the presence of water as a solvent. By this, it is meant that water is the only solvent.
Suitably, steps (i) to (iii) are carried out without isolation of 2-(azidomethyl)-1,3- difluorobenzene of formula III and without isolation of methyl 1-(2,6-difluorobenzyl)-1 H- 1 ,2,3-triazoie-4-carboxylic acid of formula IV. In other words, neither one of these intermediates is isolated from the reaction mixture as a solid.
In an embodiment, the process is a one-pot process. In other words, all the steps that result in rufinamide in the process of the present invention are carried out in a single reaction vessel.
According to another aspect of the present invention, there is provided rufinamide prepared according to the process of the present invention.
According to another aspect of the present invention, there is provided a pharmaceutical composition comprising rufinamide prepared according to the process of the present invention together with one or more pharmaceutically acceptable excipients. According to another aspect of the present invention, there is provided rufinamide prepared according to the process of the present invention for use in treating epilepsy or subindications thereof.
According to another aspect of the present invention, there is provided a method of treating epilepsy or a subindication thereof, the method comprising administering to a subject in need thereof a therapeutically effective amount of rufinamide prepared according to the process of the present invention.
Thus, the present invention is advantageous as it provides an improved process for preparing rufinamide which process involves the use of methyl propiolate. The use of methyl propiolate, rather than propiolic acid, as in the prior art, reduces the reaction times and allows the use of water as the solvent, which is environmentally friendly and safe. According to another aspect of the present invention, there is provided the use of methyl propiolate in a process for preparing rufinamide. In an embodiment, the process is carried out in water as a solvent. Suitably, the process is a one-pot process.
The process may involve reacting 2-(azidomethyl)-1,3-difluorobenzene of formula III with methyl propiolate, to obtain methyl 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4- carboxylic acid of formula IV, and converting the methyl 1-(2,6-difluorobenzyl)-1 H-1 ,2,3- triazole-4-carboxylic acid of formula IV to rufinamide.
Figure imgf000008_0001
IV The same reaction conditions as described above in relation to the first aspect of the invention may be applied to this step.
The conversion of methyl 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxylic acid of formula IV to rufinamide may comprise reacting the methyl 1-(2,6-difluorobenzyl)-1H- 1 ,2,3-triazole-4-carboxylic acid of formula IV with ammonia to obtain rufinamide.
The same reaction conditions as described above in relation to the first aspect of the invention may be applied to this step.
The 2-(azidomethyl)-1,3-difluorobenzene of formula III may have been prepared by reacting a 2,6-difluorobenzylhalide of formula II, wherein X is chloride, bromide or iodide, with an azide to obtain the 2-(azidomethyl)-1 ,3-difluorobenzene of formula 111.
Figure imgf000009_0001
The same reaction conditions as described above in relation to the first aspect of the invention may be applied to this step.
Detailed Description of the Invention
The invention will now be described in detail in connection with certain preferred and optional embodiments, so that various aspects thereof may be more fully understood and appreciated. The process of the present invention involves the synthesis of rufinamide and may employ water as a solvent which contributes to green chemistry. The present invention describes a practical, economical and efficient synthesis for the preparation of rufinamide. This process is particularly advantageous in comparison with known methods because the reaction may be carried out without isolating the intermediates formed by the preceding step. The process of the present invention eliminates the risk of handling hazardous chemicals, the enhanced cost associated with multiple reactors, and it reduces the reaction time and cleanup, thus making the process more industrially viable.
In an embodiment of the present invention, there is provided an improved process for synthesis of rufinamide as depicted below in reaction Scheme 2,
Figure imgf000010_0001
Scheme 2 Accordingly, in an embodiment, the present invention provides a process for the preparation of rufinamide of formula I, which process comprises: (a) reacting 2,6- difluorobenzylchloride of formula HA
Figure imgf000011_0001
HA
with sodium azide in the presence of water to obtain a 2-(azidomethyl)-1,3- difluorobenzene intermediate of formula III;
Figure imgf000011_0002
(b) reacting the intermediate of formula III with methyl propiolate in the presence of water as the solvent to obtain methyl 1-(2,6-difluorobenzyl)-1H-1 ,2,3-triazole-4- carboxylic acid of formula IV; and
Figure imgf000011_0003
IV
(c) reacting the intermediate of formula IV with ammonia to yield rufinamide of formula In an embodiment, the process is carried out without isolation of 2-(azidomethyl)-1 ,3- difluorobenzene and without isolation of methyl 1-(2,6-difluorobenzyl)-1H-1 ,2,3-triazole- 4-carboxylic acid. In another embodiment, the process is carried out as a one-pot process. Alternatively, the process may be carried out with isolation of the intermediates.
In an embodiment, water is the solvent in each of steps (i), (ii) and (iii). Water is advantageous over the environmentally-unfriendly organic solvents as used in the prior art. Further, the use of water reduces the production cost, simplifies the work-up and minimizes the effluent disposal problem.
In an embodiment, step (a) is carried out at a temperature ranging from about 600C to about 800C, preferably ranging from about 700C to about 750C.
In an embodiment, the reaction time to produce the azide intermediate of formula III ranges from about 25 hours to about 40 hours, and preferably from about 25 hours to about 30 hours.
In another embodiment, in step (b), the 2-(azidomethyl)-1 )3-difluorobenzene intermediate is subjected to a ring closure reaction by adding methyl propiolate dropwise at room temperature (about 250C) and then allowing the temperature to rise to a temperature ranging from about 500C to about 750C, preferably to a temperature ranging from about 600C to about 650C, and the time required for the reaction ranges from about 4 to about 5 hours.
In yet another embodiment, the amidation reaction of step (c) is carried out using ammonia which may be in the form of gaseous ammonia, liquid ammonia or aqueous ammonia, preferably aqueous ammonia. Suitably, the concentration of the aqueous ammonia ranges from about 20% to about 25%. Typically, the aqueous ammonia is added dropwise. The reaction is preferably carried out at a temperature ranging from about 650C to about 800C, more preferably from about 700C to about 750C.
The reaction contents are cooled to room temperature (about 250C), washed with water and then dried under vacuum to obtain solid rufinamide.
In still another embodiment rufinamide is prepared by isolating the intermediates obtained at each preceding step.
The invention also relates to the use of rufinamide preferably in the form of pharmaceutical preparations for the treatment of epilepsy and subindications thereof.
The following examples, which include preferred embodiments, will serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purpose of illustrative discussion of preferred embodiments of the invention.
Examples:
Example 1 - One-pot Preparation of 1-[(2,6-Difluorophenyl)methyl]-1H-1,2,3- triazole-4-carboxamide (rufinamide):
In a 250 ml round bottom flask, 2,6-difluorobenzylbromide (0.024 mol, 5 g), sodium azide (0.026 mol, 1.72 g) and water (50 ml) were added. The reaction mixture was heated to 700C to 750C for 30 hours and formation of the azide intermediate was monitored by thin layer chromatography (TLC). After the completion of reaction, the reaction contents were cooled to room temperature and then to this methyl propiolate (0.024 mol, 2.1 ml) was added dropwise, maintaining the contents at room temperature. On complete addition, the mixture was again heated at 600C to 650C for 4 to 5 hours. After the reaction was completed, the contents were cooled to room temperature and to this 25% aqueous ammonia (40 ml) solution was added dropwise. The reaction contents were heated to 700C to 750C for 4 to 5 hours and then gradually cooled to room temperature. The solid obtained was filtered and washed with water. The product was dried under vacuum at 700C - 750C to give 3.0 g of rufinamide.
Example 2 - Multistep Preparation of 1-[(2,6-Difluorophenyl)methyl]-1H-1,2,3- triazole-4-carboxamide (rufinamide):
Step A - Preparation of 2-(azidomethyl)-1,3-difluorobenzene:
To a 250 ml round bottom flask, 2,6-difluorobenzylbromide (0.024 mol, 5 g), sodium azide (0.026 mol, 1.72 g) and water (50 ml) were charged. The reaction mixture was heated to 700C to 750C for 30 hours and formation of azide intermediate (99.4%) was monitored by gas chromatography. After completion of the reaction, the contents were cooled to room temperature. The layers of the reaction mixture were separated to obtain an upper water layer and a lower azide intermediate layer. The lower layer was then concentrated and dried under vacuum to obtain 3.8 g of the product.
Step B - Preparation of methyl 1-(2,6-difluorobenzyl)-1H-1,2,3-trϊazole-4- carboxylic acid:
In a 250 ml round bottom flask, 2-(azidomethyl)-1 ,3-difluorobenzene (0.0207 mol, 3.0 g) as obtained from step A and water (50 ml) were charged. To this mixture methyl propiolate (0.0207 mol, 2.1 ml) was added dropwise at room temperature and then heated to 600C to 650C for 4 to 5 hours. The progress of the reaction was monitored by TLC. After the completion of reaction, the reaction mixture was cooled to room temperature. The solid obtained was filtered and then washed with water (10 ml). The product was dried under vacuum at 500C to 550C to give 2.5 g of methyl 1-(2,6- difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxylic acid.
Step C - Preparation of rufinamide: A mixture of intermediate obtained from step B (0.0098 mol, 2.5 g), and 20% aqueous ammonia solution (0.196 mol, 15 ml) was added to a 250 ml round bottom flask. The mixture was then stirred at 700C to 750C for 5 to 6 hours. After the completion of reaction, as monitored by TLC, the reaction mixture was cooled to room temperature. The solid obtained was filtered, washed with water and dried under vacuum at 600C to 650C to give a solid product (1.7 g).
It will be appreciated that the invention may be modified within the scope of the appended claims.

Claims

1. A process for the preparation of rufinamide of formula
Figure imgf000016_0001
which process comprises: (i) reacting a 2,6-difluorobenzylhalide of formula II, wherein X is chloride, bromide or iodide, with an azide to obtain 2-(azidomethyl)-1 ,3- difluorobenzene of formula III;
Figure imgf000016_0002
(ii) reacting 2-(azidomethyl)-1 ,3-difluorobenzene of formula III with methyl propiolate to obtain methyl 1-(2,6-difluorobenzyl)-1H-1 ,2,3-triazole-4-carboxylic acid of formula IV; and
Figure imgf000016_0003
III IV (iii) reacting methyl 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid of formula IV with ammonia to obtain rufinamide of formula I.
2. A process according to claim 1, wherein X is chloride.
3. A process according to claim 1 , wherein X is bromide.
4. A process according to claim 1 , 2 or 3, wherein the azide is an alkali metal azide.
5. A process according to claim 4, wherein the alkali metal azide is sodium azide or potassium azide.
6. A process according to claim 4, wherein the alkali metal azide is sodium azide.
7. A process according to claim 1 , 2 or 3, wherein the azide is trimethylsilyl azide.
8. A process according to claim 1 , 2 or 3, wherein the azide is diphenylphosphoryl azide.
9. A process according to any preceding claim, wherein the ammonia in step (iii) is in the form of aqueous ammonia.
10. A process according to any preceding claim, wherein all the reaction steps are carried out in the presence of water as a solvent.
11. A process according to any preceding claim, wherein steps (i) to (iii) are carried out without isolation of 2-(azidomethyl)-1 ,3-difluorobenzene of formula III and without isolation of methyl 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxylic acid of formula IV.
12. A process according to any preceding claim, wherein the process is a one-pot process.
13. The use of methyl propiolate in a process for preparing rufinamide.
14. Use according to claim 13, wherein the process is carried out in water as a solvent.
15. Use according to claim 13 or 14, wherein the process is a one-pot process.
16. Use according to claim 13, 14 or 15, wherein the process for preparing rufinamide is as defined in any one of claims 1 to 12.
17. A process substantially as herein described with reference to the Examples.
PCT/GB2009/002419 2008-10-13 2009-10-09 Process for the preparation of rufinamide WO2010043849A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2009305255A AU2009305255B2 (en) 2008-10-13 2009-10-09 Process for the preparation of rufinamide
JP2011530559A JP2012505191A (en) 2008-10-13 2009-10-09 Method for producing rufinamide
NZ591725A NZ591725A (en) 2008-10-13 2009-10-09 PROCESS FOR THE PREPARATION OF RUFINAMIDE which is also known as 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
US13/063,440 US8183269B2 (en) 2008-10-13 2009-10-09 Process for the preparation of rufinamide
CA2736703A CA2736703A1 (en) 2008-10-13 2009-10-09 Process for the preparation of rufinamide
EP09744712A EP2334653A1 (en) 2008-10-13 2009-10-13 Process for the preparation of rufinamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2190/MUM/2008 2008-10-13
IN2190MU2008 2008-10-13

Publications (2)

Publication Number Publication Date
WO2010043849A1 true WO2010043849A1 (en) 2010-04-22
WO2010043849A8 WO2010043849A8 (en) 2011-06-30

Family

ID=41786401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/002419 WO2010043849A1 (en) 2008-10-13 2009-10-09 Process for the preparation of rufinamide

Country Status (9)

Country Link
US (1) US8183269B2 (en)
EP (1) EP2334653A1 (en)
JP (2) JP2012505191A (en)
KR (1) KR20110067022A (en)
AU (1) AU2009305255B2 (en)
CA (1) CA2736703A1 (en)
NZ (1) NZ591725A (en)
WO (1) WO2010043849A1 (en)
ZA (1) ZA201101836B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219752A (en) * 2011-04-21 2011-10-19 北京赛科药业有限责任公司 Novel crystal form D of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
WO2011135105A1 (en) 2010-04-30 2011-11-03 Laboratorios Lesvi, S.L. Improved process for preparing rufinamide intermediate
WO2012025936A2 (en) 2010-08-25 2012-03-01 Ramamohan Rao Davuluri Improved process for the preparation of rufinamide
WO2012032540A1 (en) 2010-09-06 2012-03-15 Indoco Remedies Limited Process for preparation of fluorinated triazole compound
US8183269B2 (en) 2008-10-13 2012-05-22 Cipla Limited Process for the preparation of rufinamide
CN103539750A (en) * 2012-07-09 2014-01-29 旭和(天津)医药科技有限公司 Synthesis process of rufinamide
WO2014072992A1 (en) 2012-11-12 2014-05-15 Aarti Industries Limited A process for preparing triazole compounds
WO2014120994A1 (en) * 2013-01-31 2014-08-07 The Johns Hopkins University Rufinamide and derivatives and their use in modulating the gating process of human voltage-gated sodium channels
WO2014121383A1 (en) * 2013-02-11 2014-08-14 Apotex Technologies Inc. A process for the preparation of rufinamide and intermediates thereof
CN109438374A (en) * 2018-10-10 2019-03-08 凯莱英医药集团(天津)股份有限公司 Rufinamide is continuously synthesizing to method

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140357871A1 (en) 2012-01-10 2014-12-04 Lupin Limited Process for preparation of rufinamide
KR20190081386A (en) 2017-12-29 2019-07-09 강원대학교산학협력단 Composition for preventing the ischemia stroke disease containing rufinamide
CN114106211A (en) * 2021-08-31 2022-03-01 海南医学院 Yunnan chanterelle polysaccharide and separation and purification method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
WO1998056772A1 (en) * 1997-06-10 1998-12-17 Novartis Ag Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127665A (en) 1996-07-11 2004-03-28 Novartis Ag Process for preparing 1-substituted 4-cyano-1,2,3,-triazoles
NZ591725A (en) 2008-10-13 2012-09-28 Cipla Ltd PROCESS FOR THE PREPARATION OF RUFINAMIDE which is also known as 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
WO1998056772A1 (en) * 1997-06-10 1998-12-17 Novartis Ag Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2334653A1 *
SULTAN T. ABU-ORABI ET AL.: "Effect of solvant and reaction time on the products of the 1,3-dipolar cycloaddition of substituted benzyl azides with di-tert-butyl acetylenedicarboxylate", GAZZETTA CHIMICA ITALIANA, vol. 122, 1992, pages 29 - 33, XP008120316 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183269B2 (en) 2008-10-13 2012-05-22 Cipla Limited Process for the preparation of rufinamide
WO2011135105A1 (en) 2010-04-30 2011-11-03 Laboratorios Lesvi, S.L. Improved process for preparing rufinamide intermediate
US8884026B2 (en) 2010-04-30 2014-11-11 Laboratorios Lesvi, S.L. Process for preparing rufinamide intermediate
JP2013525413A (en) * 2010-04-30 2013-06-20 ラボラトリオス レスヴィ,エス.エル. Improved process for the preparation of rufinamide intermediate
JP2013538208A (en) * 2010-08-25 2013-10-10 ラオ ダヴルリ,ラマモハン Improved rufinamide preparation process
WO2012025936A2 (en) 2010-08-25 2012-03-01 Ramamohan Rao Davuluri Improved process for the preparation of rufinamide
WO2012032540A1 (en) 2010-09-06 2012-03-15 Indoco Remedies Limited Process for preparation of fluorinated triazole compound
CN102219752A (en) * 2011-04-21 2011-10-19 北京赛科药业有限责任公司 Novel crystal form D of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
CN103539750A (en) * 2012-07-09 2014-01-29 旭和(天津)医药科技有限公司 Synthesis process of rufinamide
WO2014072992A1 (en) 2012-11-12 2014-05-15 Aarti Industries Limited A process for preparing triazole compounds
WO2014120994A1 (en) * 2013-01-31 2014-08-07 The Johns Hopkins University Rufinamide and derivatives and their use in modulating the gating process of human voltage-gated sodium channels
WO2014121383A1 (en) * 2013-02-11 2014-08-14 Apotex Technologies Inc. A process for the preparation of rufinamide and intermediates thereof
CN109438374A (en) * 2018-10-10 2019-03-08 凯莱英医药集团(天津)股份有限公司 Rufinamide is continuously synthesizing to method
CN109438374B (en) * 2018-10-10 2020-10-30 凯莱英医药集团(天津)股份有限公司 Continuous synthesis method of rufinamide

Also Published As

Publication number Publication date
AU2009305255A8 (en) 2011-08-25
ZA201101836B (en) 2011-10-26
US8183269B2 (en) 2012-05-22
JP2015096515A (en) 2015-05-21
AU2009305255A1 (en) 2010-04-22
EP2334653A1 (en) 2011-06-22
US20110207938A1 (en) 2011-08-25
NZ591725A (en) 2012-09-28
JP2012505191A (en) 2012-03-01
AU2009305255B2 (en) 2014-02-06
WO2010043849A8 (en) 2011-06-30
KR20110067022A (en) 2011-06-20
CA2736703A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
AU2009305255B2 (en) Process for the preparation of rufinamide
EP3882237B1 (en) Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
EP2230234B1 (en) Process for the preparation of rufinamide
JP6108112B2 (en) Improved rufinamide preparation process
US7705159B2 (en) Process for the preparation of letrozole
EP2066646B1 (en) Process for the preparation of pure anastrozole
HU203327B (en) Process for producing fluorinated benzyl-thiazol derivatives and pharmaceutical compositions containing them
EP3577099B1 (en) A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
CZ4299A3 (en) Process for preparing 1-substituted 4-cyan-1,2,3- triazoles
US7368464B2 (en) Preparation for the production of 1,2,4-triazolylmethyl-oxiranes
CN110563659B (en) Method for preparing 1,2, 3-triazole compound by heterogeneous copper catalysis in one pot
JP4502225B2 (en) Process for producing 5-substituted 2-chloropyridine
CN114478411A (en) Method for synthesizing prothioconazole
JP3407088B2 (en) Method for producing triazole derivative and intermediate thereof
EP1471058B1 (en) Process for producing 1,2,3-triazole compound
JP5106574B2 (en) Method for producing 1-substituted-4-carbamoyl-1,2,4-triazol-5-one derivative
WO1988003531A1 (en) Cardiotonic imidazolylphenylpyrrol-2-ones
JPH07300463A (en) Production of 5-alkoxyhydantoin compound
JPH07300464A (en) Production of 5-alkoxyhydantoin compound
PL204392B1 (en) Method of obtaining 2,2'-(5-(1H-1,2,4-triazol-1-)-ylmethyl)-1,3-phenylene)di(2-methylpropionitrile)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09744712

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2009744712

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009744712

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009305255

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2736703

Country of ref document: CA

Ref document number: 475/MUMNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 591725

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 20117006738

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009305255

Country of ref document: AU

Date of ref document: 20091013

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011530559

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13063440

Country of ref document: US